P53-regulated LncRNAs in Cancers: from Proliferation and Metastasis to Therapy

Overview

Journal Cancer Gene Ther

Specialties Genetics
Oncology
Pharmacology

Date 2023 Sep 7

PMID 37679529

Authors

Kaixin Yang

Yinan Xiao

Linghui Zhong

Wenyang Zhang

Peng Wang

Yaru Ren

Lei Shi

Affiliations

Soon will be listed here.

Abstract

Long non-coding RNAs (lncRNAs) have been identified as master gene regulators through various mechanisms such as transcription, translation, protein modification and RNA-protein complexes. LncRNA dysregulation is frequently associated with a variety of biological functions and human diseases including cancer. The p53 network is a key tumor-suppressive mechanism that transcriptionally activates target genes to suppress cellular proliferation in human malignancies. Recent research indicates that lncRNAs play an important role in the p53 signaling pathway. In this review, we summarize the current knowledge of lncRNAs in p53-relevant functions and provide an overview of how these altered lncRNAs contribute to tumor initiation and progression. We also discuss the association between lncRNA and up- or downstream genes of p53. These findings imply that lncRNAs can help identify cellular vulnerabilities that may prove to be promising potential biomarkers and therapeutic targets for cancer treatment.

References

Levine A, Momand J, Finlay C . The p53 tumour suppressor gene. Nature. 1991; 351(6326):453-6. DOI: 10.1038/351453a0. View

Lane D, Benchimol S . p53: oncogene or anti-oncogene?. Genes Dev. 1990; 4(1):1-8. DOI: 10.1101/gad.4.1.1. View

Freed-Pastor W, Prives C . Mutant p53: one name, many proteins. Genes Dev. 2012; 26(12):1268-86. PMC: 3387655. DOI: 10.1101/gad.190678.112. View

Braithwaite A, Sturzbecher H, Addison C, Palmer C, Rudge K, Jenkins J . Mouse p53 inhibits SV40 origin-dependent DNA replication. Nature. 1987; 329(6138):458-60. DOI: 10.1038/329458a0. View

Marur S, DSouza G, Westra W, Forastiere A . HPV-associated head and neck cancer: a virus-related cancer epidemic. Lancet Oncol. 2010; 11(8):781-9. PMC: 5242182. DOI: 10.1016/S1470-2045(10)70017-6. View

Lane D . Cancer. p53, guardian of the genome. Nature. 1992; 358(6381):15-6. DOI: 10.1038/358015a0. View

Bykov V, Eriksson S, Bianchi J, Wiman K . Targeting mutant p53 for efficient cancer therapy. Nat Rev Cancer. 2017; 18(2):89-102. DOI: 10.1038/nrc.2017.109. View

Engeland K . Cell cycle regulation: p53-p21-RB signaling. Cell Death Differ. 2022; 29(5):946-960. PMC: 9090780. DOI: 10.1038/s41418-022-00988-z. View

Liu T, Lam V, Thieme E, Sun D, Wang X, Xu F . Pharmacologic Targeting of Mcl-1 Induces Mitochondrial Dysfunction and Apoptosis in B-Cell Lymphoma Cells in a and Dependent Manner. Clin Cancer Res. 2021; 27(17):4910-4922. PMC: 8416922. DOI: 10.1158/1078-0432.CCR-21-0464. View

10.

Wang J, Thomas H, Li Z, Yeo N, Scott H, Dang N . Puma, noxa, p53, and p63 differentially mediate stress pathway induced apoptosis. Cell Death Dis. 2021; 12(7):659. PMC: 8245518. DOI: 10.1038/s41419-021-03902-6. View

11.

Aubrey B, Kelly G, Janic A, Herold M, Strasser A . How does p53 induce apoptosis and how does this relate to p53-mediated tumour suppression?. Cell Death Differ. 2017; 25(1):104-113. PMC: 5729529. DOI: 10.1038/cdd.2017.169. View

12.

Kim E, Giese A, Deppert W . Wild-type p53 in cancer cells: when a guardian turns into a blackguard. Biochem Pharmacol. 2008; 77(1):11-20. DOI: 10.1016/j.bcp.2008.08.030. View

13.

Zhu J, Sammons M, Donahue G, Dou Z, Vedadi M, Getlik M . Gain-of-function p53 mutants co-opt chromatin pathways to drive cancer growth. Nature. 2015; 525(7568):206-11. PMC: 4568559. DOI: 10.1038/nature15251. View

14.

Duffy M, Crown J . Drugging "undruggable" genes for cancer treatment: Are we making progress?. Int J Cancer. 2020; 148(1):8-17. DOI: 10.1002/ijc.33197. View

15.

Birsen R, Larrue C, Decroocq J, Johnson N, Guiraud N, Gotanegre M . APR-246 induces early cell death by ferroptosis in acute myeloid leukemia. Haematologica. 2021; 107(2):403-416. PMC: 8804578. DOI: 10.3324/haematol.2020.259531. View

16.

Hong Y, Ren T, Wang X, Liu X, Fei Y, Meng S . APR-246 triggers ferritinophagy and ferroptosis of diffuse large B-cell lymphoma cells with distinct TP53 mutations. Leukemia. 2022; 36(9):2269-2280. DOI: 10.1038/s41375-022-01634-w. View

17.

Toden S, Zumwalt T, Goel A . Non-coding RNAs and potential therapeutic targeting in cancer. Biochim Biophys Acta Rev Cancer. 2020; 1875(1):188491. PMC: 7856203. DOI: 10.1016/j.bbcan.2020.188491. View

18.

Palazzo A, Koonin E . Functional Long Non-coding RNAs Evolve from Junk Transcripts. Cell. 2020; 183(5):1151-1161. DOI: 10.1016/j.cell.2020.09.047. View

19.

Esteller M . Non-coding RNAs in human disease. Nat Rev Genet. 2011; 12(12):861-74. DOI: 10.1038/nrg3074. View

20.

Ali S, Peffers M, Ormseth M, Jurisica I, Kapoor M . The non-coding RNA interactome in joint health and disease. Nat Rev Rheumatol. 2021; 17(11):692-705. DOI: 10.1038/s41584-021-00687-y. View